URGN - ユ―ロジェン・ファ―マ (UroGen Pharma Ltd.)

URGNのニュース

   UroGen pharma reports inducement grant to 13 new employees  2021/12/03 16:37:05 Seeking Alpha
   UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)  2021/12/03 13:00:00 Kwhen Finance
   UroGen Pharma Ltd. (NASDAQ:URGN) Expected to Announce Earnings of -$1.27 Per Share  2021/12/02 21:08:44 Transcript Daily
Wall Street brokerages predict that UroGen Pharma Ltd. (NASDAQ:URGN) will post earnings of ($1.27) per share for the current quarter, Zacks Investment Research reports. Two analysts have provided estimates for UroGen Pharmas earnings, with estimates ranging from ($1.39) to ($1.08). UroGen Pharma reported earnings of ($1.38) per share during the same quarter last year, which []
   UroGen Pharma Ltd. (NASDAQ:URGN) CFO Sells $31,121.61 in Stock  2021/12/02 19:12:42 Transcript Daily
UroGen Pharma Ltd. (NASDAQ:URGN) CFO Molly Henderson sold 2,587 shares of the companys stock in a transaction that occurred on Tuesday, November 30th. The shares were sold at an average price of $12.03, for a total value of $31,121.61. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is []
   Nuveen Asset Management LLC Cuts Stock Position in UroGen Pharma Ltd. (NASDAQ:URGN)  2021/11/27 10:44:48 Dakota Financial News
Nuveen Asset Management LLC decreased its holdings in shares of UroGen Pharma Ltd. (NASDAQ:URGN) by 5.9% during the second quarter, according to its most recent disclosure with the SEC. The fund owned 96,600 shares of the companys stock after selling 6,054 shares during the period. Nuveen Asset Management LLC owned approximately 0.46% of UroGen Pharma []
   UroGen Pharma (URGN) Presents At HealthVirtual Conference - Slideshow  2021/07/16 21:52:32 Seeking Alpha
   UroGen Pharma sees Q2 net revenue of $13M, above consensus  2021/07/14 13:02:44 Seeking Alpha
   UroGen Pharma Reports Strong Preliminary Jelmyto® Sales for Second Quarter 2021  2021/07/14 12:00:00 Business Wire
PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, today announced that it expects net product revenue from Jelmyto sales for the second quarter ended June 30, 2021, to be approximately $13.0 million, representing an increase of over 70% compared to the first quarter of 2021 and the highest quarterly sales since Jelmyto was launched in June
   Here is What Hedge Funds Think About UroGen Pharma Ltd. (URGN)  2021/06/30 14:08:39 Insider Monkey
   UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - June 04, 2021  2021/06/04 00:00:00 BioSpace
UroGen Pharma Ltd. a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, announced the grants of inducement restricted stock units to eleven new employees in connection with their employment with UroGen.
   Here is What Hedge Funds Think About UroGen Pharma Ltd. (URGN)  2021/06/30 14:08:39 Insider Monkey
   UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - June 04, 2021  2021/06/04 00:00:00 BioSpace
UroGen Pharma Ltd. a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, announced the grants of inducement restricted stock units to eleven new employees in connection with their employment with UroGen.
   UroGen Pharma Announces June 2021 Conference Schedule  2021/05/25 00:00:00 BioSpace
UroGen Pharma Ltd., a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, announced that it will present at the following virtual conferences in June
   UroGen Pharma Ltd Shares Close the Week 21.9% Higher - Weekly Wrap  2021/05/21 22:30:00 Kwhen Finance
UroGen Pharma Ltd (URGN) shares closed this week 21.9% higher than it did at the end of last week. The stock is currently up 2.8% year-to-date, down 27.0% over the past 12 months, and up 32.5% over the past five years. This week, the Dow Jones Industrial Average fell 0.4%, and the S&P 500 fell 0.4%. Trading Activity Shares traded as high as $19.00 and as low as $15.11 this week.Shares closed 4e+1% below its 52-week high and 3e+1% above its 52-week low.Trading volume this week was 29.4% lower than the 10-day average and 12.3% lower than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.1. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price beats the S&P 500 Index this week, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price beats the Dow Jones Industrial Average this week, lags it on a 1-year basis, and lags it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector this week, lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -90.0% The company's stock price performance over the past 12 months lags the peer average by -163.6% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   Looking Into UroGen Pharma''s Return On Capital Employed  2021/05/21 16:49:46 Benzinga
UroGen Pharma (NASDAQ: URGN ) reported Q1 sales of $7.49 million. Earnings fell to a loss of $26.11 million, resulting in a 4.18% decrease from last quarter. In Q4, UroGen Pharma brought in $7.97 million in sales but lost $27.25 million in earnings. What Is ROCE? Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts in a company''s ROCE. A higher ROCE is Full story available on Benzinga.com

calendar